UP!

News

Aegerion Pharmaceuticals, Inc. (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q1 2017 2017-05-08 Future report Set alerts
Q4 2016 2017-02-23 Future report Set alerts
Q3 2016 2016-11-03 -0.37 -0.90
Q2 2016 2016-08-09 -0.72 -1.59
Q1 2016 2016-05-16 -1.72 -2.22
Q4 2015 2016-02-25 -1.26 -1.26
Q3 2015 2015-11-09 -0.34 -0.34
Q2 2015 2015-08-05 -0.37 -0.39
Q1 2015 2015-05-04 -0.55 -0.55
Q4 2014 2015-02-26 -0.29 -0.29

Ratings

2016-05-17 Boost Price Target Leerink Swann Outperform $6.00 to $15.00
2016-04-17 Reiterated Rating Cowen and Company Hold
2016-02-26 Reiterated Rating Leerink Swann Outperform $31.00 to $15.00
2016-02-12 Downgrade Bank of America Neutral to Underperform $6.00
2016-02-12 Downgrade Bank of America Corp. Neutral to Underperform $6.00
2016-01-11 Reiterated Rating Cowen and Company Market Perform $15.00
2015-12-21 Upgrade Guggenheim Sell to Buy $7.00 to $13.00
2015-11-17 Reiterated Rating Leerink Swann Buy
2015-11-11 Reiterated Rating JPMorgan Chase & Co. Neutral $24.00
2015-11-11 Upgrade Bank of America Underperform to Neutral $21.00 to $13.00
2015-11-10 Lower Price Target Leerink Swann Outperform $38.00 to $31.00
2015-11-10 Lower Price Target Jefferies Group Buy $26.00 to $16.00
2015-11-10 Lower Price Target Guggenheim $9.00 to $7.00
2015-11-10 Reiterated Rating Cowen and Company Hold $25.00 to $15.00
2015-08-06 Reiterated Rating JPMorgan Chase & Co. Neutral $24.00
2015-07-28 Reiterated Rating Leerink Swann Outperform $38.00
2015-07-28 Upgrade Jefferies Group Hold to Buy $26.00
2015-07-27 Reiterated Rating JPMorgan Chase & Co. Neutral
2015-07-06 Downgrade Guggenheim Neutral to Sell
2015-05-26 Reiterated Rating Needham & Company LLC Hold
2015-05-05 Reiterated Rating JPMorgan Chase & Co. Neutral $24.00
2015-02-27 Reiterated Rating JPMorgan Chase & Co. Neutral $24.00
2015-01-12 Reiterated Rating JPMorgan Chase & Co. Hold
2014-10-31 Downgrade Bank of America Buy to Underperform
2014-10-31 Downgrade Needham & Company LLC Buy to Hold
2014-10-31 Downgrade JPMorgan Chase & Co. Overweight to Neutral $24.00 to $43.00
2014-10-31 Downgrade Deutsche Bank Buy to Hold $58.00 to $26.00
2014-10-31 Downgrade Jefferies Group Buy to Hold $61.00 to $24.00
2014-10-31 Downgrade Deutsche Bank AG Buy to Hold $58.00 to $26.00
2014-10-16 Downgrade Bank of America Buy
2014-08-15 Reiterated Rating Deutsche Bank Buy $70.00 to $58.00
2014-05-27 Initiated Coverage Goldman Sachs Sell $27.00
2014-05-07 Reiterated FBR Capital Outperform $111 to $107
2014-05-07 Downgrade Citigroup Inc. Outperform to Market Perform
2014-05-07 Lower Price Target Deutsche Bank $115.00 to $70.00
2014-05-07 Downgrade Cowen and Company Outperform to Market Perform $85.00 to $36.00
2014-05-07 Lower Price Target FBR & Co. Outperform $111.00 to $107.00
2014-05-07 Lower Price Target Jefferies Group $80.00 to $61.00
2014-04-21 Upgrade Ned Davis Research Sell to Neutral
2014-03-28 Lower Price Target Jefferies Group Buy $90.00 to $80.00
2014-03-20 Lower Price Target Leerink Swann $86.00 to $66.00
2014-03-19 Lower Price Target Cowen and Company $95.00 to $85.00
2014-01-10 Lower Price Target Cowen and Company $105.00 to $95.00
2013-11-19 Reiterated Rating Canaccord Genuity Buy $110.00
2013-11-19 Reiterated Rating Leerink Swann Outperform $106.00
2013-11-13 Boost Price Target Deutsche Bank Buy $107.00 to $115.00
2013-10-31 Boost Price Target Jefferies Group Buy $92.00 to $102.00
2013-10-31 Boost Price Target Cowen and Company Outperform $105.00
2013-10-30 Initiated Coverage FBR & Co. Outperform $105.00 to $111.00
2013-07-31 Reiterated Canaccord Genuity Buy $90 to $110
2013-07-30 Reiterated Needham Buy $100
2013-07-22 Reiterated Needham Buy $50 to $100
2013-05-29 Reiterated Canaccord Genuity Buy $54 to $90
2013-01-09 Reiterated Needham Buy $30 to $36
2012-10-18 Reiterated Needham Buy $22 to $30
2012-10-18 Reiterated Capstone Investments Buy $21 to $27
2012-10-12 Initiated Capstone Investments Buy $21
2011-11-09 Initiated Deutsche Bank Buy $19
2011-06-28 Initiated Global Hunter Securities Buy $23
2010-12-06 Initiated Collins Stewart Buy $16
2016-05-17 Boost Price Target Leerink Swann Outperform $6.00 to $15.00
2016-04-17 Reiterated Rating Cowen and Company Hold
2016-02-26 Reiterated Rating Leerink Swann Outperform $31.00 to $15.00
2016-02-12 Downgrade Bank of America Neutral to Underperform $6.00
2016-02-12 Downgrade Bank of America Corp. Neutral to Underperform $6.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In AEGR 1 funds of 2184 total. Show all

Fund name Ticker shares
MANAGED ACCOUNT ADVISORS LLC 7753

Major Shareholders

Name Relationship Total Shares Holding stocks
Broadfin Healthcare Master Fund Ltd 13.57%  (4010291) AEGR / FLML / MELA / MRTX / PETX / PGNX / QLTI / REPH /
PERCEPTIVE ADVISORS LLC 9.56%  (2823426) ACRX / AEGR / ALDX / BIOD / FOLD / LJPC / PLCC / RPRX / VSAR / ZGNX /
ADVENT INTERNATIONAL CORP/MA Member of Group > 10% 8.32%  (2457879) AEGR / COTV / FIVE / VNTV /
ADVENT INTERNATIONAL LLC Member of Group > 10% 8.23%  (2430765) AEGR / FIVE / VNTV /
ADVENT HEALTHCARE & LIFE SCIENCES III LIMITED PARTNERSHIP Member of Group > 10% 3.33%  (985052) AEGR /
Scheer David 1.76%  (521350) ACHN / AEGR / TNGN /
Beer Marc D Chief Executive Officer 0.27%  (78631) AEGR / NERV /
ALTA BIOPHARMA PARTNERS III LP 0.19%  (56190) AEGR / CARA / CMRX / MGNX / SNSS /
Fitzpatrick Mark J. Chief Financial Officer 0.03%  (9500) AEGR /
VANLENT ANNE 0.01%  (4000) AEGR / AGTC / BOTA / OCRX / ONTX / QLTI /
SMITH SANDFORD D 0.01%  (2890) AEGR / APRI / CUR / CYTK / QLTI /
Carter Martha J. Chief Regulatory Officer 0.01%  (1500) AEGR / BIOD /

Comments